Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02585713 · ClinicalTrials.gov registry record · Phase 3
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
A Phase 3 study of Malignant Neoplasm and Pulmonary Embolism, sponsored by Academic and Community Cancer Research United.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 18
- Study locations
NCT02585713 is a Phase 3 study of Malignant Neoplasm and Pulmonary Embolism that has completed, run by Academic and Community Cancer Research United. The registered enrollment target is 300 participants, below the 508-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (41% lower). The trial reports 18 study locations across 13 states.
The verdict
NCT02585713, a Phase 3 study of Malignant Neoplasm and Pulmonary Embolism, has completed, sponsored by Academic and Community Cancer Research United.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 18
- Study locations
Study Summary
This randomized phase III trial studies the side effects of and compares apixaban and dalteparin in reducing blood clots in patients with cancer-related venous thromboembolism. Venous thromboembolism is a condition in which a blood clot forms in a vein and then breaks off and moves through the bloodstream. Patients with cancer are at increased risk for venous thromboembolism. Apixaban and dalteparin are drugs used to prevent blood clots from forming or to treat blood clots that have formed. It is not yet known whether apixaban or dalteparin is more effective in reducing blood clots in patients with cancer related venous thromboembolism. ADAM-VTE
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- DRUG Apixaban
- DRUG Dalteparin
Study Locations (18)
Minnesota
- Mayo Clinic - Rochester
- Coborn Cancer Center at Saint Cloud Hospital - Saint Cloud
- Metro Minnesota Community Oncology Research Consortium - Saint Louis Park
Illinois
- NorthShore University HealthSystem-Evanston Hospital - Evanston
- Illinois CancerCare-Peoria - Peoria
Iowa
- University of Iowa/Holden Comprehensive Cancer Center - Iowa City
- Siouxland Regional Cancer Center - Sioux City
Ohio
- Columbus NCI Community Oncology Research Program - Columbus
- Toledo Clinic Cancer Centers-Toledo - Toledo
Arizona
- Mayo Clinic in Arizona - Scottsdale
Florida
- Mayo Clinic in Florida - Jacksonville
Kansas
- Cancer Center of Kansas - Wichita - Wichita
Michigan
- Cancer Research Consortium of West Michigan NCORP - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2015-11-20 |
| Est. Completion | 2019-12-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02585713
The ClinicalTrials.gov registry entry for NCT02585713 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 508-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (41% lower). The listed sponsor is Academic and Community Cancer Research United, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Malignant Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Questionnaire Administration is the first listed.
NCT02585713 reports 18 study locations spanning 13 distinct geographic areas - top geographies include Minnesota, Illinois, Iowa.
Frequently Asked Questions
What is clinical trial NCT02585713 about?
NCT02585713 is a clinical study titled "Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism". This randomized phase III trial studies the side effects of and compares apixaban and dalteparin in reducing blood clots in patients with cancer-related venous thromboembolism. Venous thromboembolism is a condition in which a blood clot forms in a vein and then breaks off and moves through the blood...
What is the current status of trial NCT02585713?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2015-11-20. Estimated completion is 2019-12-24.
What conditions does trial NCT02585713 study?
This clinical trial studies the following conditions: Malignant Neoplasm, Pulmonary Embolism, Deep Vein Thrombosis, Metastatic Malignant Neoplasm, Cerebral Vein Thrombosis.
What interventions are being tested in trial NCT02585713?
The interventions under investigation include: Questionnaire Administration (OTHER), Apixaban (DRUG), Dalteparin (DRUG).
Who is sponsoring clinical trial NCT02585713?
This trial is sponsored by Academic and Community Cancer Research United, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02585713 being conducted?
This trial has 18 study locations across Arizona, Florida, Illinois, Iowa, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases
RECRUITING · Phase 3
-
Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant
COMPLETED · Phase 3
-
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
COMPLETED · Phase 3
-
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
RECRUITING · Phase 1
-
Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer
RECRUITING
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.